| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
rel-Boc-Hyp-OMe is an inactive isomer and does not have a specific biological target. It serves as a negative control in experiments where Boc-Hyp-OMe is the active compound. The active isomer, Boc-Hyp-OMe, is used as a linker in ADC and PROTAC synthesis, targeting conjugation chemistry rather than biological receptors.
|
|---|---|
| ln Vitro |
As an inactive control compound, rel-Boc-Hyp-OMe does not exhibit significant biological activity. It is used to validate that observed effects in experiments are due to the active compound (Boc-Hyp-OMe) rather than the linker moiety or other components. It shows no cytotoxicity or target modulation in standard assays.
|
| ln Vivo |
In vivo, rel-Boc-Hyp-OMe is not expected to exhibit pharmacological activity. It may be used as a negative control in animal studies to distinguish the effects of the active compound from non-specific effects. Its lack of activity makes it a valuable tool for validating experimental results in ADC and PROTAC research.
|
| Enzyme Assay |
Cell-free assays for rel-Boc-Hyp-OMe: as a control compound, it is used in binding or conjugation assays to demonstrate specificity. It can be included in HPLC or mass spectrometry analyses to confirm the identity and purity of the active compound. No specific enzyme or receptor binding assays are applicable due to its lack of biological activity.
|
| Cell Assay |
Cellular assays for rel-Boc-Hyp-OMe: cells are treated with rel-Boc-Hyp-OMe as a negative control alongside the active compound Boc-Hyp-OMe or ADC conjugates. Cell viability, proliferation, and target protein degradation (for PROTACs) are measured and compared between active compound-treated and control-treated groups to confirm specificity of the active compound's effects.
|
| Animal Protocol |
In vivo animal studies for rel-Boc-Hyp-OMe: animals are administered rel-Boc-Hyp-OMe as a control group in ADC or PROTAC efficacy studies. The compound is dosed at levels matching the active compound to control for vehicle and non-specific effects. Tumor growth inhibition, pharmacokinetic parameters, and toxicity are compared between active and control groups to validate the therapeutic effects.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of rel-Boc-Hyp-OMe are expected to be similar to those of Boc-Hyp-OMe, as they are isomers. As a small molecule (molecular weight ~245), it may have moderate oral bioavailability and tissue distribution. It is likely metabolized in the liver and excreted via the kidneys. Detailed PK data are limited.
|
| Toxicity/Toxicokinetics |
Toxicity of rel-Boc-Hyp-OMe: as an inactive isomer used as a control compound, it is expected to have low toxicity. No specific toxicity data are available. It is for research use only and not intended for human therapeutic applications. Standard laboratory safety precautions should be followed during handling.
|
| References |
[1]. Beck A, et al. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017;16(5):315-337.
[2]. Nalawansha DA, et al. PROTACs: An Emerging Therapeutic Modality in Precision Medicine. Cell Chem Biol. 2020;27(8):998-985. |
| Additional Infomation |
See other relationships...
rel-Boc-Hyp-OMe is a research-grade compound used as an experimental control in ADC and PROTAC research. Its primary application is to validate the specificity and activity of Boc-Hyp-OMe-based conjugates. It is not a therapeutic agent and has no clinical applications. It is available as a reference standard for analytical and pharmacological studies. |
| Molecular Formula |
C11H19NO5
|
|---|---|
| Molecular Weight |
245.272263765335
|
| Exact Mass |
245.126
|
| CAS # |
1145663-09-7
|
| Related CAS # |
Boc-Hyp-OMe;74844-91-0
|
| PubChem CID |
2734883
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
0.6
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
17
|
| Complexity |
310
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
CC(C)(C)OC(=O)N1C[C@@H](C[C@H]1C(=O)OC)O
|
| InChi Key |
MZMNEDXVUJLQAF-SFYZADRCSA-N
|
| InChi Code |
InChI=1S/C11H19NO5/c1-11(2,3)17-10(15)12-6-7(13)5-8(12)9(14)16-4/h7-8,13H,5-6H2,1-4H3/t7-,8+/m1/s1
|
| Chemical Name |
1-O-tert-butyl 2-O-methyl (2S,4R)-4-hydroxypyrrolidine-1,2-dicarboxylate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.0771 mL | 20.3857 mL | 40.7714 mL | |
| 5 mM | 0.8154 mL | 4.0771 mL | 8.1543 mL | |
| 10 mM | 0.4077 mL | 2.0386 mL | 4.0771 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
